Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2006 Jun 19;94(12):1803-8.
doi: 10.1038/sj.bjc.6603196.

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer

K Yamaguchi  1 , T Shimamura, I Hyodo, W Koizumi, T Doi, H Narahara, Y Komatsu, T Kato, S Saitoh, T Akiya, M Munakata, Y Miyata, Y Maeda, H Takiuchi, S Nakano, T Esaki, F Kinjo, Y Sakata
Affiliations
Clinical Trial

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer

K Yamaguchi et al. Br J Cancer. .

Abstract

The aims of this phase I/II study of docetaxel and S-1 were to determine the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), and recommended dose (RD) in the phase I part and to explore the tumour response, survival and safety in the phase II part. Patients with histologically- or cytologically confirmed unresectable or recurrent gastric cancer were eligible. Treatment consisted of intravenous docetaxel on day 1 (starting dose 50 mg m(-2)) and oral S-1 at a fixed dose of 40 mg m(-2) twice daily on days 1-14, every 4 weeks up to six cycles. Nine patients took part in the phase I portion of the study. The MTD of docetaxel was determined to be 50 mg m(-2), with the DLTs of grade 3 infection associated with grade 3 neutropenia and grade 4 neutropenia during S-1 administration. The RD of docetaxel was 40 mg m(-2) in combination with S-1 40 mg m(-2) b.i.d. The efficacy and safety of this regimen was therefore assessed in 46 patients with at least one measurable lesion. The overall response rate and estimated median overall survival were 46% (95% CI, 31-61%) and 14.0 months (8.3-17.3 months), respectively. The most common grade 3/4 toxicity was neutropenia (67% of patients), which was predictable and manageable. This regimen showed promising activity with moderate toxicities in advanced gastric cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The cumulative probability of survivals. The solid and dotted lines present overall and progression-free survivals estimated by the Kaplan–Meier method in 46 patients, respectively.
See this image and copyright information in PMC

References

    1. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Filho SC, Majlis A, Assadourian S, Van Cutsem E (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23: 5660–5667 - PubMed
    1. Alberts SR, Cervantes A, van de Velde CJH (2003) Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14(Suppl 2): ii31–ii36 - PubMed
    1. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F (1995) Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: preclinical experience. Anticancer Drugs 6: 339–368 - PubMed
    1. Chollet P, Schoffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J, Fumoleau P, EORTC Early Clinical Studies Group (2003) Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39: 1264–1270 - PubMed
    1. Constenla M, Garcia-Arroyo R, Lorenzo I, Carrete N, Campos B, Palacios P (2002) Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Gastric Cancer 5: 142–147 - PubMed

Publication types

MeSH terms